vxa-g1.1-nn
Vaccineexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2019 (NCT03897309)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- NorovirusImmunity, active
immunity, active - norovirus
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06944717 | Phase 1 | Mar 3, 2025 | Vaxart |
| NCT07254728 | Phase 1 | Oct 27, 2023 | Vaxart |
| NCT05212168 | Phase 1/Phase 2 (Phase 2) | Jan 28, 2022 | Vaxart |
| NCT05213728 | Phase 1 | Jan 24, 2022 | Vaxart |
| NCT04875676 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2021 | ICON, Vaxart |
| NCT04854746 | Phase 1 | Apr 26, 2021 | Vaxart |
| NCT03897309 | Phase 1 | Mar 20, 2019 | Rapid Medical Research, Inc., Vaxart |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaxart | For profit | 7 | 7 | 2 | 2019 |
| ICON | For profit | 1 | 0 | 1 | 2021 |
| Rapid Medical Research, Inc. | For profit | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1